UA103261U - Method for monitoring radiation treatment NSCLC - Google Patents

Method for monitoring radiation treatment NSCLC

Info

Publication number
UA103261U
UA103261U UAU201505393U UAU201505393U UA103261U UA 103261 U UA103261 U UA 103261U UA U201505393 U UAU201505393 U UA U201505393U UA U201505393 U UAU201505393 U UA U201505393U UA 103261 U UA103261 U UA 103261U
Authority
UA
Ukraine
Prior art keywords
vegf
radiation treatment
blood
patient
monitoring radiation
Prior art date
Application number
UAU201505393U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Віра Василівна Карвасарська
Наталія Андріївна Мітряєва
Віктор Петрович Старенький
Лідія Володимирівна Гребіник
Наталія Володимирівна Білозор
Тетяна Станіславівна Бакай
Original Assignee
Державна Установа "Інститут Медичної Радіології Ім. С.П. Григор'Єва Національної Академії Медичних Наук України"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Державна Установа "Інститут Медичної Радіології Ім. С.П. Григор'Єва Національної Академії Медичних Наук України" filed Critical Державна Установа "Інститут Медичної Радіології Ім. С.П. Григор'Єва Національної Академії Медичних Наук України"
Priority to UAU201505393U priority Critical patent/UA103261U/en
Publication of UA103261U publication Critical patent/UA103261U/en

Links

Landscapes

  • Radiation-Therapy Devices (AREA)

Abstract

A method of monitoring nedribnoklitynnoho radiation treatment of lung cancer by radiation mode for standard fractionation primary focus and zones of regional metastases with a certain level of tumor markers in the blood of the patient. Use oncomarker VEGF, determining its level in the blood of the patient to (VEGF) 1 and one month after radiation therapy (VEGF) 2, calculate the ratio K = (VEGF) 1 / (VEGF) 2 and his value selected mode of the second phase of radiotherapy .
UAU201505393U 2015-06-02 2015-06-02 Method for monitoring radiation treatment NSCLC UA103261U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201505393U UA103261U (en) 2015-06-02 2015-06-02 Method for monitoring radiation treatment NSCLC

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201505393U UA103261U (en) 2015-06-02 2015-06-02 Method for monitoring radiation treatment NSCLC

Publications (1)

Publication Number Publication Date
UA103261U true UA103261U (en) 2015-12-10

Family

ID=55171709

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201505393U UA103261U (en) 2015-06-02 2015-06-02 Method for monitoring radiation treatment NSCLC

Country Status (1)

Country Link
UA (1) UA103261U (en)

Similar Documents

Publication Publication Date Title
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
MX2023002251A (en) Therapeutic and diagnostic methods for cancer.
MX2022006075A (en) Therapeutic and diagnostic methods for cancer.
MX2022008868A (en) Treatment of cancer with tg02.
MX2021010672A (en) Diagnosis and therapy of cancer involving cancer stem cells.
EP3867410A4 (en) Methods for determining treatment for cancer patients
MX2015014486A (en) Markers of tumor cell response to anti-cancer therapy.
MX2018004170A (en) Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof.
BR112019002036A2 (en) methods of treatment of a colorectal cancer subject, colorectal cancer treatment kit in a human subject, and drug combination for colorectal cancer therapy
IL281439A (en) Combination therapy for treating blood cancer
MX2017010341A (en) Cancer therapy with a parvovirus combined with bevacizumab.
MX2023007706A (en) Nanoparticles for use as a therapeutic vaccine.
CY1118532T1 (en) PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OR PREVENTION OF VITAMINS AND METAL SALTS IN PATIENTS WHO HAVE SUBSTITUTE
MX2017016346A (en) Methods of treatment with taselisib.
MX2021011799A (en) Semaphorin-4d antagonists for use in cancer therapy.
MX2017014540A (en) Biomarkers for a combination therapy comprising lenvatinib and everolimus.
MX2017006201A (en) Predicting response to a vegf antagonist.
MX2017003015A (en) A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof.
UA103261U (en) Method for monitoring radiation treatment NSCLC
EA201501095A1 (en) EFFECTIVE TREATMENT OF NSCLC AND A PREDICTIVE CLINICAL MARKER OF SENSITIVE TREATMENT TO TUMOR
EA201992852A1 (en) DOSAGE DIAGRAM FOR TESETAXEL AND CAPETSITABINE
EA201890014A1 (en) THERAPEUTIC COMPOSITIONS CONTAINING DIPYRIDAMOL, KITS FOR TREATMENT, CONTAINING THESE COMPOSITIONS, AND METHODS OF THEIR MANUFACTURE
SG11201808253YA (en) Marker for predicting treatment response to anti-cancer agent in solid cancer patients
EA201790093A1 (en) HEPATOCELLULAR CARCINOMA THERAPY
WO2015144184A8 (en) Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer